Abstract
A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint
Journal of clinical oncology, v 34(2_suppl), pp 185-185
10 Jan 2016
Abstract
Abstract only
185
Background: Recently approved agents that target the androgen receptor pathway emphasize the importance of the persistent activity of the androgen receptor pathway in castration-resistant prostate cancer (CRPC). This raises the possibility that agents with distinct mechanisms of action may add value. GTx-758 is a selective ERα agonist that can increase SHBG and therefore reduce biologically active testosterone (T) levels. Reported here are the results, including the final primary endpoint analysis, from the 250 mg daily GTx-758 cohort of a phase II clinical trial in men on LHRH agonists that developed CRPC. Methods: This phase II open label trial (G200712, NCT01615120) treated men with high risk nmCRPC or mCRPC with T levels < 50 ng/dL who continued to receive their current form of ADT along with either 125 mg or 250 mg of GTx-758 daily, for at least 90 days. The primary endpoint was the proportion of men with a PSA decline ≥ 50% by day 90, while secondary endpoints included serum total and free T, sex hormone binding globulin (SHBG), bone turnover markers and hot flashes. Results: The 250 mg cohort (n = 39) has completed the time period for assessment of the primary endpoint. Ten of the 39 (26%) subjects exhibited a ≥ 50% decrease in PSA by Day 90, with 11/39 (28%) by Day 120, while 18/39 (46%) had PSA declines of ≥ 30%. Median SHBG levels increased 301% of baseline, confirming the principal mechanism of drug action. While on study, median free T decreases of 44% were observed across all subjects and 20/26 (77%) of the subjects with baseline serum free T levels > 0.7 pg/ml fell below this level. Therefore, 250 mg GTx-758 decreased free testosterone levels in an additive fashion to their existing LHRH therapy. The bone turnover biomarker, C-telopeptide, decreased in 79% of the subjects. 250 mg of GTx-758 has been generally well tolerated with two reported possibly drug related SAEs (VTE and MI). Conclusions: In this phase II trial, 250 mg daily GTx-758 has activity, likely mediated by lowering free T levels in patients with CRPC on LHRH therapy, and may provide amelioration of estrogen deficiency side effects associated with ADT. Clinical trial information: NCT01615120.
Metrics
3 Record Views
Details
- Title
- A phase II open-label trial of GTx-758 in men with castration-resistant prostate cancer: Final analysis of the primary endpoint
- Creators
- Evan Y. Yu - Fred Hutch Cancer CenterMichael L. Hancock - GTx, Inc., Memphis, TNTamas Babicz - University Teaching HospitalRonald F. Tutrone - Chesapeake Urology AssociatesChristopher Ng - Tower Urology Medical GroupLaurence H. Belkoff - Urology AssociatesWilliam J. Aronson - VA Greater Los Angeles Healthcare SystemZsuzsanna Papai - Oncology Department, Medical Center, Budapest, HungaryLajos Geczi - National Institute of OncologyRobert H. Getzenberg - GTx, Inc., Memphis, TN
- Publication Details
- Journal of clinical oncology, v 34(2_suppl), pp 185-185
- Publisher
- AMER SOC CLINICAL ONCOLOGY; ALEXANDRIA
- Number of pages
- 1
- Resource Type
- Abstract
- Language
- English
- Academic Unit
- Surgery
- Web of Science ID
- WOS:000378109100185
- Other Identifier
- 991021916908104721
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Web of Science research areas
- Oncology